These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 8560679

  • 1. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [Abstract] [Full Text] [Related]

  • 2. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ.
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [Abstract] [Full Text] [Related]

  • 3. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
    [Abstract] [Full Text] [Related]

  • 4. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Eur Urol; 1996 May; 29 Suppl 2():105-9. PubMed ID: 8717471
    [Abstract] [Full Text] [Related]

  • 5. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF, Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Vogelzang NJ, Chodak GW, Klein EA, Schellenger JJ, Kolvenbag GJ.
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [Abstract] [Full Text] [Related]

  • 6. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ.
    Cancer; 1996 Nov 15; 78(10):2164-9. PubMed ID: 8918410
    [Abstract] [Full Text] [Related]

  • 7. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
    McLeod DG, Schellhammer PF, Vogelzang NJ, Soloway MS, Sharifi R, Block NL, Venner PM, Patterson AL, Sarosdy MF, Kelley RP, Kolvenbag GJ.
    Prostate; 1999 Sep 01; 40(4):218-24. PubMed ID: 10420149
    [Abstract] [Full Text] [Related]

  • 8. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Crawford ED.
    Urology; 1995 Dec 01; 46(6):899-901. PubMed ID: 7502440
    [No Abstract] [Full Text] [Related]

  • 9. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
    Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJ.
    Urology; 2000 Mar 01; 55(3):391-5; discussion 395-6. PubMed ID: 10699617
    [Abstract] [Full Text] [Related]

  • 10. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
    Kolvenbag GJ, Blackledge GR, Gotting-Smith K.
    Prostate; 1998 Jan 01; 34(1):61-72. PubMed ID: 9428389
    [Abstract] [Full Text] [Related]

  • 11. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.
    Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y.
    Jpn J Clin Oncol; 2004 Jan 01; 34(1):20-8. PubMed ID: 15020659
    [Abstract] [Full Text] [Related]

  • 12. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL, Tucker SJ.
    Oncologist; 2001 Jan 01; 6(2):177-82. PubMed ID: 11306729
    [Abstract] [Full Text] [Related]

  • 13. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
    Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y.
    Prostate Cancer Prostatic Dis; 2007 Jan 01; 10(2):194-201. PubMed ID: 17199134
    [Abstract] [Full Text] [Related]

  • 14. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y, Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.
    Cancer; 2009 Aug 01; 115(15):3437-45. PubMed ID: 19536889
    [Abstract] [Full Text] [Related]

  • 15. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G, Kolvenbag G, Nash A.
    Anticancer Drugs; 1996 Jan 01; 7(1):27-34. PubMed ID: 8742095
    [Abstract] [Full Text] [Related]

  • 16. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
    Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K, Kurume-Kumamoto Estracyt Study Group.
    Int J Urol; 2004 Feb 01; 11(2):103-9. PubMed ID: 14706014
    [Abstract] [Full Text] [Related]

  • 17. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Zerbib M, Payan C.
    Urology; 1996 Oct 01; 48(4):661-3. PubMed ID: 8886082
    [No Abstract] [Full Text] [Related]

  • 18. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK, Evans A, Hersey K, Maloni R, Hurtado-Coll A, Kulkarni G, Finelli A, Zlotta AR, Hamilton R, Gleave M, Fleshner NE.
    Clin Cancer Res; 2017 Apr 15; 23(8):1974-1980. PubMed ID: 27756786
    [Abstract] [Full Text] [Related]

  • 19. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Spano G.
    J Clin Oncol; 1999 Jul 15; 17(7):2027-38. PubMed ID: 10561254
    [Abstract] [Full Text] [Related]

  • 20. Worldwide activity and safety of bicalutamide: a summary review.
    Kolvenbag GJ, Blackledge GR.
    Urology; 1996 Jan 15; 47(1A Suppl):70-9; discussion 80-4. PubMed ID: 8560681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.